Catalyst Dossier · compiled by CeliA 🧫

Merck KGaA (MKKGY)

Pharmaceutical Preparations · market cap $72.4B · as of 2026-07-14

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-01-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Merck KGaA (MKKGY) is a German science and technology company operating in pharmaceuticals, life science tools, and performance materials, with 59,077 employees and a market cap of approximately $72.4 billion. Its pharmaceutical pipeline spans oncology, fertility, neurology, and endocrinology, with several assets in Phase 2–3. The facts provided are sparse on financials, upcoming catalysts, and recent data readouts, limiting near-term visibility.

The catalyst path

2027-01-15 (est.)Phase 2 · Bintrafusp alfaimp 7/10

Pipeline

Asset	Phase	Indication
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)	Phase 2	Infertility Implantation Failure
Saizen®	Phase 3	Idiopathic Short Stature
GONAL-f®	Phase 3	Infertility
F0434	Phase 3	Diabetic Neuropathies
MSJ-0011	Phase 3	Anovulation
Cisplatin/Carboplatin	Phase 2	Squamous Cell Carcinoma of the Head and Neck
RNF	Phase 3	Multiple Sclerosis
Tepotinib	Phase 2	Carcinoma, Hepatocellular
M7824	Phase 3	Non-small Cell Lung Cancer
Precemtabart tocentecan	Phase 3	Metastatic Colorectal Cancer
GEN-001	Phase 2	Gastric Cancer
Cilengitide	Phase 3	Glioblastoma
Single low dose cyclophosphamide	Phase 3	Non-small Cell Lung Cancer
M2591 25 mg QD	Phase 2	Rheumatoid Arthritis
Bintrafusp alfa	Phase 3	Advanced Soft-tissue Sarcoma
Pimasertib	Phase 2	Pancreatic Adenocarcinoma
Peposertib 50 mg	Phase 2	Locally Advanced Rectal Cancer
Nirogacestat	Phase 2	Desmoid Tumor
Enpatoran	Phase 3	Systematic Lupus Erythematosus
Cilengitide (2-times weekly)	Phase 2	Glioblastoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MKKGY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.